SCHEMBL8277672

SCHEMBL8277672

CC(C)Cc1ccc(C(N)=O)cc1Nc1nc2c(ccc3cnccc32)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XIAP P98170 1/20 0.38
DYRK1A Q13627 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
PARP14 Q460N5 3/20 0.34
TNIK Q9UKE5 1/20 0.34
MAPK14 Q16539 2/20 0.33
AR P10275 1/20 0.33
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
HIPK2 Q9H2X6 1/20 0.32
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
KMT2A Q03164 1/20 0.32
CD38 P28907 1/20 0.32
PIM1 P11309 1/20 0.32
CSNK2A2 P19784 1/20 0.32
CSNK2B P67870 1/20 0.32
CSNK2A1 P68400 1/20 0.32
PIM2 Q9P1W9 1/20 0.32
DPP4 P27487 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8277671 0.93 XIAP (0.38) XIAPDYRK1AHRH4PARP14TNIK
SCHEMBL8278683 0.84 XIAP (0.39) XIAPDYRK1APARP14TNIKMAPK14
SCHEMBL8277681 0.84 MEN1 (0.35) XIAPCCNA2CDK2MEN1KMT2A
SCHEMBL8277670 0.83 TNIK (0.39) XIAPDYRK1AHRH4TNIKAR
SCHEMBL6128202 0.82 CHRM4 (0.41) MEN1POLBKMT2ACSNK2A1
SCHEMBL8277560 0.82 SYK (0.37) XIAPDYRK1APARP14MAPK14AR
SCHEMBL6118093 0.80 HRH4 (0.38) DYRK1AHRH4PARP14TNIKMAPK14
SCHEMBL8277561 0.80 DYRK1A (0.35) XIAPDYRK1AHRH4PARP14MAPK14
SCHEMBL8277609 0.79 DYRK1A (0.35) XIAPDYRK1AHRH4PARP14MAPK14
SCHEMBL8277535 0.79 DYRK1A (0.35) XIAPDYRK1AHRH4PARP14MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129811-A1 TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129811-A1 TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP3, MMP13 XIAP 965/4885DYRK1A 4569/4885HRH4 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.